主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2020, Vol. 43 ›› Issue (2): 133-140.doi: 10.3969/j.issn.1006-2157.2020.02.007

• 中药药理 • 上一篇    下一篇

基于iTRAQ技术探讨复方钩藤降压片干预自发性高血压大鼠心肌组织差异蛋白的研究*

王健章, 俞赟丰, 周曼丽, 冯宇, 郭志华, 简维雄#   

  1. 湖南中医药大学 湖南 410208
  • 收稿日期:2019-09-02 发布日期:2020-03-24
  • 通讯作者: 简维雄,男,博士,副教授,研究方向:心病中医证治机理研究,E-mail:daxiong20001977@163.com
  • 作者简介:王健章,男,在读硕士生
  • 基金资助:
    *国家自然科学基金面上项目(No.81774207),重大新药创制科技重大专项(No.2019ZX09301103),湖南省自然科学基金面上项目(No.2018JJ2291)

Intervention of Compound Uncaria Tablets on myocardial differential protein in spontaneously hypertensive rats based on iTRAQ technology*

Wang Jianzhang, Yu Yunfeng, Zhou Manli, Feng Yu, Guo Zhihua, Jian Weixiong#   

  1. Hunan University of Chinese Medicine, Hunan 410208, China
  • Received:2019-09-02 Published:2020-03-24
  • Contact: A/Prof.Jian Weixiong,Ph. D., Hunan University of Chinese Medicine, Hunan 410208, China.Email: daxiong20001977@163.com
  • Supported by:
    National Natural Science Foundation of China(No.81774207);National Major Scientific and Technological SpecialProject for Significant New Drug Developmnet(No.2019ZX09301103);National Natural Science Foundation of Hunan Province(No. 2018JJ2291)

摘要: 目的 研究复方钩藤降压片干预自发性高血压大鼠(SHR)心肌组织蛋白质变化及高血压左心室肥厚潜在机制。方法 将16只SHR分为2组后,治疗组予以复方钩藤降压片灌胃干预,对照组予以蒸馏水灌胃,干预12周后采取大鼠心肌组织蛋白质进行同位素标记相对和绝对定量(iTRAQ)检测分析。通过对富集Pathway分析,得到差异蛋白及通路,并将得到的差异蛋白利用STRING数据库绘制差异蛋白功能联系。结果 差异蛋白富集Pathway分析提示存在11条通路。差异蛋白中上调蛋白6种,分别为:转胶蛋白、碳酸酐酶3、S期激酶相关蛋白1、C反应蛋白、纤维蛋白5、C-1-四氢叶酸合成酶;下调蛋白12种,分别为:谷胱甘肽S-转移酶、Ighg3蛋白、组氨酸三联核苷酸结合蛋白2、60S核糖体蛋白L4、40S核糖体蛋白S6、60S核糖体蛋白L13、14-3-3蛋白、LOC100911337蛋白、谷胱甘肽过氧化物酶1、丝氨酸羟甲基转移酶、蛋白激酶B、泛素-40S核糖体蛋白S27A。在string绘制的关系网中:60S核糖体蛋白L4、40S核糖体蛋白S6、60S核糖体蛋白L13、泛素-40S核糖体蛋白S27A之间关系最为密切。结论 复方钩藤降压片对高血压左心室肥厚的干预主要与改善血供、优化能量代谢、抑制心肌细胞的异常生长、增加血管和心脏的纤维蛋白密切相关;高血压左心室肥厚的发生可能与核糖体蛋白有关。

关键词: 复方钩藤降压片, 高血压, 心肌组织, 核糖体蛋白, 同位素标记相对和绝对定量

Abstract: Objective To study the protein changes in the intervention of the Compound Uncaria Tablets in Spontaneously Hypertensive Rats (SHR) and the potential mechanism of left ventricular hypertrophy in hypertension. Methods 16SHRs were divided into two groups. The treatment group was gavaged with the Compound Uncaria Tablets, and the control group was gavaged with distilled water. After 12 weeks of intervention, the myocardial tissue protein was taken and tested by iTRAQ assay analysis. By analyzing the enrichment of pathways, the differential proteins and pathways were obtained, and furtherly mapped using the STRING database. Results The pathway enrichment analysis of the differential protein indicated that there were 11 pathways. The iTRAQ analysis of the differential protein indicated that there were 6 up-regulated proteins: transgelatin, carbonic anhydrase 3, S-phase kinase-associated protein 1, C-reactive protein, fibrin 5, and C-1-tetrahydrofolate synthetase; and there were 12 down-regulated proteins: glutathione S-transferase, Ighg3, histidine trinucleotide binding protein 2, 60S ribosomal protein L4, 40S ribosomal protein S6, 60S ribosomal protein L13, 14-3-3 protein, protein LOC100911337, glutathione peroxidase 1, serine hydroxymethyltransferase, protein kinase B, and ubiquitin -40S ribosomal protein S27A.In the relational network drawn by string: 60S ribosomal protein L4, 40S ribosomal protein S6, 60S ribosomal protein L13, and ubiquitin-40S ribosomal protein S27A are most closely related. Conclusion The intervention of Compound Uncaria Tablets on hypertensive left ventricular hypertrophy is possibly mainly related to improving blood supply, optimizing energy metabolism, inhibiting abnormal growth of cardiomyocytes and increasing fibrin of blood vessels and heart. The occurrence of hypertensive left ventricular hypertrophy may be related to ribosomal proteins.

Key words: Compound Uncaria Tablets, hypertension, left ventricular hypertrophy, ribosomal protein, iTRAQ

中图分类号: 

  • R285.5